Daiichi Sankyo To Use Ranbaxy To Market Branded Drugs Abroad
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo intends to use its ownership of Ranbaxy Laboratories to sell its branded drugs in China, Europe and the United States as soon as they lose patent protection